000181877 001__ 181877
000181877 005__ 20230208173455.0
000181877 0247_ $$2CORDIS$$aG:(EU-Grant)690966$$d690966
000181877 0247_ $$2CORDIS$$aG:(EU-Call)H2020-MSCA-RISE-2015$$dH2020-MSCA-RISE-2015
000181877 0247_ $$2originalID$$acorda__h2020::690966
000181877 035__ $$aG:(EU-Grant)690966
000181877 150__ $$aPRoteome-based assessment of vascular disease for the Establishment of a Translational REsearch plATform$$y2016-01-01 - 2019-12-31
000181877 371__ $$aInserm$$bINSERM$$dFrance$$ehttp://english.inserm.fr/$$vCORDIS
000181877 371__ $$aEMERGENTEC BIODEVELOPMENT GMBH$$dAustria$$vCORDIS
000181877 371__ $$aIDRYMA IATROVIOLOGIKON EREUNON AKADEMIAS ATHINON$$bBIOMEDICAL RESEARCH FOUNDATION, ACADEMY OF ATHENS$$dGreece$$ehttp://www.bioacademy.gr$$vCORDIS
000181877 371__ $$aHYBRIDSTAT PREDICTIVE ANALYTICS OE$$bHYBRIDSTAT$$dGreece$$ehttp://www.hybridstat.gr$$vCORDIS
000181877 371__ $$aMosaiques diagnostics and therapeutics AG (Germany)$$bMosaiques diagnostics and therapeutics AG (Germany)$$dGermany$$ehttp://mosaiques-diagnostics.com/diapatpcms/mosaiquescms/front_content.php$$vCORDIS
000181877 372__ $$aH2020-MSCA-RISE-2015$$s2016-01-01$$t2019-12-31
000181877 450__ $$aPRETREAT$$wd$$y2016-01-01 - 2019-12-31
000181877 5101_ $$0I:(DE-588b)5098525-5$$2CORDIS$$aEuropean Union
000181877 680__ $$aCardiovascular disease (VD) is the leading cause of mortality and morbidity in Europe and worldwide. The objective of the PRETREAT consortium is to generate a joint SME/academic European preclinical platform for providing services for detection of VD and drug development. This platform will combine the use of urinary and/or blood peptidomics in humans and in preclinical animal models of VD, together with bioinformatics and systems biology, in order to better detect, stratify and decipher the molecular mechanisms of VD, develop new animal models with high similarity to human disease, and provide new tools for obtaining information on novel drug targets.
PRETREAT builds on the FP7 project Sysvasc (systems biology to identify molecular targets for vascular disease treatment, 2014-2018) and the combined expertise of the PRETREAT partners in clinical proteomics, proteomics, animal models and system medicine as the pillars to implement this platform. The work will be carried out in an extensive exchange program totaling 27 secondments. Main objectives during the secondments include establishment of the link between urinary markers and the pathophysiology of VD, identification of additional animal VD models with similarity to human VD, development of “humanized” body fluid readouts in VD models, establishment of a VD protein-centric database in order to automatically link urinary peptides to in situ changes and provide information on drug targets, and provide proof-of-concept of the utility of the proposed platform. These secondments will in parallel serve to keep information flowing within the project, increase individual research efficiency and create a multi-disciplinary working chain, train personnel, and prepare the sustainability of the results after the project. To complete training, 3 monthly webinars and four workshops are planned.
000181877 909CO $$ooai:juser.fz-juelich.de:277460$$pauthority$$pauthority:GRANT
000181877 909CO $$ooai:juser.fz-juelich.de:277460
000181877 970__ $$aoai:dnet:corda__h2020::d79401d8840e88d385e689c3e54d94be
000181877 980__ $$aG
000181877 980__ $$aCORDIS
000181877 980__ $$aAUTHORITY